Thyroid Hormone for Thyroid Cancer
Launched by UNIVERSITY MEDICAL CENTER GRONINGEN · Oct 16, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how two different thyroid hormones, liothyronine (L-T3) and levothyroxine (L-T4), affect patients with differentiated thyroid cancer (DTC) after they stop taking their usual thyroid medication. The study will take place at two medical centers and will compare how these hormones influence important factors like thyroid function, overall health, weight, and quality of life.
To participate, individuals must have a confirmed diagnosis of differentiated thyroid cancer and be at high risk for recurrence, as determined by their doctor. They should also be ready for a specific treatment involving stopping their thyroid medication temporarily. However, pregnant individuals and those with certain health conditions or a history of mental health issues won't be eligible. This trial is not yet recruiting participants, but for those who qualify, it could provide valuable insights into managing thyroid cancer treatment effectively.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histologically confirmed DTC (papillary thyroid carcinoma, follicular thyroid carcinoma, oncocytic thyroid carcinoma)
- • Classified as high-risk DTC according to the ATA guidelines (1) or, patients for whom the risk of a recurrence is estimated to be higher based on clinical features (assessed by their treating physician).
- • Prepared for RAI-therapy with TH-withdrawal
- • Patients have to be fit to adhere to the study protocol
- • Patients have to be able to read and understand the Dutch language
- Exclusion Criteria:
- • Pregnancy
- • Patients with a psychiatric history or history of depression
- • Patients with comorbidities, such as severe heart failure, (poorly controlled) atrial fibrillation, of which the treating physician decides that L-T3 is unsuitable.
- Conditions or drugs interfering with thyroid hormone uptake:
- • - Patients with a history of atrophic gastriti
About University Medical Center Groningen
University Medical Center Groningen (UMCG) is a leading academic medical center in the Netherlands, renowned for its commitment to innovative research, high-quality patient care, and extensive education in the medical field. As a prominent sponsor of clinical trials, UMCG leverages its multidisciplinary expertise and state-of-the-art facilities to advance medical knowledge and improve therapeutic outcomes. The center fosters collaboration among researchers, healthcare professionals, and industry partners, aiming to translate scientific discoveries into effective treatments that enhance patient health and well-being. With a focus on ethical standards and regulatory compliance, UMCG is dedicated to conducting clinical trials that contribute to the advancement of medicine and the betterment of society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Groningen, , Netherlands
Nijmegen, , Netherlands
Patients applied
Trial Officials
Wouter Zandee, MD/PhD
Principal Investigator
UMCG
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported